

## **UK Modern Slavery Act 2015**

### **Amgen Ltd., Public Statement**

In accordance with the UK Modern Slavery Act 2015, Section 54(1), Amgen Ltd has published the following public statement regarding its compliance with the Act and the steps it takes to support the goals of the Act.

#### **Organizational Structure, Business and Supply Chains**

Amgen, Inc. (Amgen) is a global biotechnology company focusing on the discovery, development, manufacture and delivery of innovative human therapeutics for patients suffering from serious illnesses. Amgen Ltd is a wholly owned subsidiary of Amgen Inc.

The role of Amgen Ltd. is to provide certain pre-launch, clinical development support and related services to Amgen Inc. In addition to its local clinical development support activities, Amgen Ltd. also operates as Amgen's European R&D headquarters and provides global and regional development support to Amgen Inc. Further, Amgen Ltd. undertakes sales and marketing activities in the UK.

Amgen operates state of the art process development capabilities and commercial biologics manufacturing facilities, primarily in the US and Puerto Rico. In addition, Amgen operates a commercial manufacturing site in Ireland (Dun Laoghaire) with considerable investment locally. Medicines distributed by Amgen in the UK are manufactured primarily in these Amgen's facilities.

In the course of its operations Amgen is a consumer of a variety of goods and services. This document sets out the steps taken by Amgen to comply with the Modern Slavery Act and to support its goals. As detailed below, Amgen uses a combination of staff education and training, internal procedures and external audits to ensure compliance with policies and codes of conduct to uphold and enforce standards relating to the requirements of the Act.

#### **Relevant Policies**

The corporate policies of Amgen, Inc. apply to Amgen, Ltd. Those corporate policies include a number of requirements designed to eliminate support for modern slavery or human trafficking. These include the following:

1. A [Supplier Code of Conduct](#) that explicitly states that suppliers shall not use forced, bonded, involuntary, slave or indentured labor or involuntary prison labor. Other components of the Supplier Code of Conduct include requirements for suppliers to uphold the human rights of workers, a ban on use of child labor, and a prohibition on suppliers' use of corporal punishment or mental or physical coercion of workers. The Supplier Code of Conduct also asks suppliers to encourage their staff to report any concerns or illegal activities in the workplace freely and without fear of reprisal.
2. A [Staff Code of Conduct](#) that requires all Amgen employees to follow all applicable laws and conduct business with integrity. This is reinforced through mandatory annual training for all employees and on-going compliance monitoring.
3. A [public statement in accordance with the California Supply Chain Transparency Act](#) that states Amgen's expectations for suppliers to comply with all laws, including those prohibiting use of child, involuntary or slave labor.

#### **Due Diligence and Risk Management**

To minimize the risk of modern slavery within Amgen's supply chain, Amgen conducts a number of due diligence activities to identify risks and address any issues uncovered. Specific due diligence and risk management activities include:

1. A continuous supply chain risk assessment process that identifies any issues that may cause disruptions in Amgen’s supply chain. These include the risks associated with non-compliance with regulatory requirements, including those banning modern slavery and forced labor. A variety of mechanisms are used to monitor the performance of key suppliers and identify areas of risk. This risk assessment process, which is performed for all suppliers related to the satisfaction of Good Manufacturing Practices (GMP) requirements (a set of regulatory requirements associated with the manufacturing of medicines), includes assessments of risks associated with geography as well as type of business. As necessary, corrective actions are required of suppliers.
2. Amgen also performs audits of all GMP-accredited suppliers, covering the specific requirements of GMP. These on-site audits are designed to verify compliance with all requirements for Amgen GMP suppliers, including compliance with applicable regulations. These audits are performed every 1 – 4 years, depending upon the nature of the supplier.
3. During 2016, the Supplier Code of Conduct (referenced previously) was enhanced to explicitly include (amongst many other requirements) a prohibition on modern slavery and forced labor. The Supplier Code of Conduct is incorporated (via reference) into all Purchase Orders as well as the terms and conditions of our contracts with suppliers.
4. In parallel with the enhancement of the Supplier Code of Conduct, a Supplier Sustainability Program has been formalized, and includes development of expanded monitoring of supplier performance. This will improve our ability to monitor performance of suppliers across a broad range of sustainability issues, including modern slavery, to ensure alignment with the requirements of the Supplier Code of Conduct. This additional monitoring and assessment will initially focus on our most critical suppliers and be expanded to cover more of Amgen’s supply chain over time.

**Performance Indicators**

To evaluate the on-going effectiveness of its efforts to manage the risks associated with modern slavery in its supply chain, Amgen utilizes the following key performance indicators:

1. The number of GMP suppliers passing through our risk assessment process;
2. The number of GMP suppliers audited;
3. The percentage of employees receiving “Do the Right Thing” training.

**Employee Training**

All Amgen staff receive training on our Staff Code of Conduct, as well as annual refresher training regarding the need to act ethically and in compliance with all applicable laws and regulations as well as Amgen policies. This “Do The Right Thing” training emphasizes the obligation to report any observances of non-compliance with laws, regulations or Amgen policies.

Signed on behalf of Amgen Ltd:

<b>John Kearney</b>	<b>22 November 2016</b>	<b>Chris Walker</b>	<b>23 November 2016</b>
<hr/>		<hr/>	
John Kearney	Date	Chris Walker	Date
General Manager, UK & Ireland		Vice President, Regulatory Affairs - Europe	